Click Here to return To Results

 

Interferon Beta-1a for Early Multiple Sclerosis: CHAMPS Trial Subgroup Analyses Ann Neurol 51:481-490, Beck,R.W.,et al, 2002 See this aricle in Pubmed Article Abstract The objective of this work was to assess the effect of interferon ¯-1a (Avonex) on the rate of development of clinically definite multiple sclerosis and brain magnetic resonance imaging changes in subgroups based on type of presenting event, baseline brain magnetic resonance imaging parameters, and demographic factors in the Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) trial. Interferon ¯-1a is beneficial when initiated at the first clinical demyelinatin g event in patients with brain magnetic resonance imaging evidence of subclinical demyelination. The beneficial effect is present for optic neuritis, brainstem-cerebellar syndromes, and spinal cord syndromes.

Related Tags

(click to filter results - removes previous filter) interferon interferon beta 1-a MRI,abnormal MRI,demyelinating disease multiple sclerosis multiple sclerosis,monosymptomatic multiple sclerosis,treatment of multiple sclerosis,treatment of,first attack treatment of neurologic disorder

Click Here to return To Results